Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?

It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient’s clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.

1. Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Research and Practice. 2017;4(1):R33–41. DOI: 10.1530/ERP-17-0013

2. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

3. Cardinale DM, Zaninotto M, Cipolla CM, Passino C, Plebani M, Clerico A. Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clinical Chemistry and Laboratory Medicine. 2021;59(1):51–7. DOI: 10.1515/cclm-2020-0566

4. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal - Cardiovascular Imaging. 2022;23(10):e333–465. DOI: 10.1093/ehjci/jeac106

5. Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020;22(11):1945–60. DOI: 10.1002/ejhf.1920

6. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

7. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063

8. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Nikitin I.G., Potievskaya V.I., Shupenina E.Yu. Guidance letter for cardiologists and primary care physicians on primary prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology. Cardiovascular Therapy and Prevention. 2023;22(7):119–27. DOI: 10.15829/1728-8800-2023-3684

9. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Nikitin I.G., Potievskaya V.I., Shupenina E.Yu. Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology. Cardiovascular Therapy and Prevention. 2023;22(7):109–18. DOI: 10.15829/1728-8800-2023-3685

10. Muslov S.A., Vyzhigin D.A., Vasyuk Yu.A., Zavyalova A.I., Shupenina E.Yu., Nikishenko A.N. et al. Certificate of state registration of the computer program RU 2023687737. “RCVTH-calculator. Application 2023687588. Registration date 01.12.2023. Av. at: https://elibrary.ru/item.asp?id=56015608&ysclid=m24rmgvhw0 968720344.

11. Vasyuk Yu.A., Muslov S.A., Shupenina E.Yu., Zavyalova A.I., Vyzhigin D.A., Nikishenko A.N. Certificate of state registration of the computer program RU 2024613769. Android risk calculator for cardio and vasotoxicity of chemotherapy for cancer patients for mobile devices ‘ARQUTH-2.0’. Registration date 06.02.2024. Av. at: https://elibrary.ru/item.asp?id=60785406&ysclid=m24rnq3x5o271433758.

12. Chang Y-J, Chang C-H, Peng C-L, Wu H-C, Lin H-C, Wang J-Y et al. Measurement equivalence and feasibility of the EORTC QLQ-PR25: paper-and-pencil versus touch-screen administration. Health and Quality of Life Outcomes. 2014;12(1):23. DOI: 10.1186/1477-7525-12-23

13. Zavyalov A.A., Kashurnikov A.Yu., Andreev D.A. Specialized electronic questionnaires of radiation therapy outcomes and quality of cancer patient’s life. Doctor and information technology. 2021;2:28–35. DOI: 10.25881/18110193_2021_2_28

14. Advances in Patient Reported Outcomes: Integration and Innovation: Leeds, UK. 13 June 2019. Journal of Patient-Reported Outcomes. 2020;4(S1):28. DOI: 10.1186/s41687-020-00193-x 15. Muslov S.A., Maev I.V., Arutyunov S.D., Pertsov S.S., Maslak A.A., Solodov A.A. Measuring quality of life indicators in medicine based on classical and modern theory. - M.: Prakticheskaya meditsina, 2023. - 216p. ISBN 978-5-98811-756-8